A Phase 1, Two-Part Study of NIP292 Tablets in Healthy Adult Subjects: Part 1 - Randomized, Double-Blind, Placebo-Controlled Assessment of Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses; Part 2 - Randomized, Double-Blind, Placebo-Controlled Assessment of Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses.
Latest Information Update: 27 Mar 2023
At a glance
- Drugs NIP 292 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
Most Recent Events
- 22 Mar 2023 Status changed from recruiting to completed.
- 05 Apr 2022 Planned End Date changed from 30 Dec 2021 to 30 Dec 2022.
- 05 Apr 2022 Planned primary completion date changed from 30 Dec 2021 to 30 Aug 2022.